Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

Sabine Tejpar(Unknown), Volker Heinemann(LMU Klinikum), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Josep Tabernero(Deaconess Hospital), Regina Esser(Merck (Germany)), Frank Beier(Western University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Sebastian Stintzing(Humboldt-Universität zu Berlin)
JAMA Oncology
October 10, 2016
10.1001/jamaoncol.2016.3797
Cited by 722

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k